Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 12-Mar-24 9:58 PM View:  | Farwell Wildon Chief Medical Officer | Dyne Therapeutics, Inc. (DYN) | 12-Mar-24 | Sale (Planned) | 1,030 | $25.58 | $26,347.40 | (< 1%) 151.59K to 150.56K | |
| 12-Mar-24 9:56 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Sale (Planned) | 7,769 | $26.12 | $202,926.00 | (1%) 545.77K to 538.0K | |
| 13-Mar-24 6:04 AM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Option Sale | 17,825 | $25.48 | $454,181.00 | (11%) 159.01K to 141.18K | |
| 13-Mar-24 6:04 AM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Option Exercise | 17,825 | $5.54 | $98,750.50 | 13% 141.18K to 159.01K | |
| 12-Mar-24 9:56 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Option Sale | 50,000 | $25.61 | $1,280,510.00 | (8%) 604.38K to 554.38K | |
| 13-Mar-24 6:04 AM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Sale (Planned) | 1,776 | $25.71 | $45,661.00 | (1%) 141.18K to 139.41K | |
| 12-Mar-24 9:42 PM View: | Beskrovnaya Oxana Chief Scientific Officer | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Private Sale (Planned) | 2,081 | $25.70 | $53,481.70 | (1%) 154.43K to 152.35K | |
| 12-Mar-24 9:57 PM View: | Scalzo Richard William SVP, Head of Finance & Admin. | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Sale (Planned) | 2,672 | $25.28 | $67,541.50 | (2%) 121.95K to 119.28K | |
| 12-Mar-24 9:58 PM View: | Farwell Wildon Chief Medical Officer | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Private Sale (Planned) | 1,585 | $25.70 | $40,734.50 | (1%) 153.18K to 151.59K | |
| 12-Mar-24 9:56 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Option Exercise | 50,000 | $5.54 | $277,000.00 | 9% 554.38K to 604.38K | |
| 12-Mar-24 9:56 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Sale | 8,618 | $25.61 | $220,708.00 | (2%) 554.38K to 545.77K | |
| 13-Mar-24 6:04 AM View: | High Susanna Gatti Chief Operating Officer | Dyne Therapeutics, Inc. (DYN) | 11-Mar-24 | Sale (Planned) | 2,292 | $25.70 | $58,904.40 | (1%) 159.09K to 156.8K | |
| 12-Mar-24 9:57 PM View: | Scalzo Richard William SVP, Head of Finance & Admin. | Dyne Therapeutics, Inc. (DYN) | 08-Mar-24 | Option Sale | 86,252 | $26.22 | $2,261,470.00 | (41%) 208.21K to 121.95K | |
| 12-Mar-24 9:56 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 08-Mar-24 | Option Exercise | 363,343 | $5.54 | $2,012,920.00 | 66% 554.38K to 917.73K | |
| 13-Mar-24 6:04 AM View: | High Susanna Gatti Chief Operating Officer | Dyne Therapeutics, Inc. (DYN) | 08-Mar-24 | Private Sale | 27,199 | $26.67 | $725,344.00 | (15%) 186.29K to 159.09K | |
| 13-Mar-24 6:04 AM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 08-Mar-24 | Option Sale | 90,000 | $26.24 | $2,361,530.00 | (39%) 231.18K to 141.18K | |
| 12-Mar-24 9:57 PM View: | Scalzo Richard William SVP, Head of Finance & Admin. | Dyne Therapeutics, Inc. (DYN) | 08-Mar-24 | Option Exercise | 86,252 | $5.54 | $477,836.00 | 71% 121.95K to 208.21K | |
| 13-Mar-24 6:04 AM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 08-Mar-24 | Option Exercise | 90,000 | $5.54 | $498,600.00 | 64% 141.18K to 231.18K | |
| 12-Mar-24 9:56 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 08-Mar-24 | Option Sale | 363,343 | $25.93 | $9,421,630.00 | (40%) 917.73K to 554.38K | |
| 11-Mar-24 9:56 PM View: | Beskrovnaya Oxana Chief Scientific Officer | Dyne Therapeutics, Inc. (DYN) | 07-Mar-24 | Private Sale (Planned) | 2,373 | $25.85 | $61,342.10 | (2%) 156.81K to 154.43K | |
| 11-Mar-24 9:56 PM View: | High Susanna Gatti Chief Operating Officer | Dyne Therapeutics, Inc. (DYN) | 07-Mar-24 | Private Sale (Planned) | 1,591 | $25.85 | $41,127.40 | (< 1%) 187.88K to 186.29K | |
| 11-Mar-24 9:52 PM View: | Farwell Wildon Chief Medical Officer | Dyne Therapeutics, Inc. (DYN) | 07-Mar-24 | Private Sale (Planned) | 9,921 | $25.86 | $256,585.00 | (6%) 163.1K to 153.18K | |
| 11-Mar-24 9:50 PM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 07-Mar-24 | Private Sale (Planned) | 2,434 | $25.85 | $62,918.90 | (2%) 143.62K to 141.18K | |
| 11-Mar-24 9:57 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 07-Mar-24 | Private Sale (Planned) | 9,086 | $25.85 | $234,873.00 | (2%) 563.47K to 554.38K | |
| 11-Mar-24 9:45 PM View: | Scalzo Richard William SVP, Head of Finance & Admin. | Dyne Therapeutics, Inc. (DYN) | 07-Mar-24 | Private Sale (Planned) | 2,273 | $25.85 | $58,757.10 | (2%) 124.23K to 121.95K | |
| 01-Mar-24 9:37 PM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 01-Mar-24 | Planned Option Sale | 24,260 | $28.63 | $694,495.00 | (14%) 167.88K to 143.62K | |
| 05-Mar-24 5:08 PM View: | Rhodes Jason P Director | Dyne Therapeutics, Inc. (DYN) | 01-Mar-24 | Private Sale (Planned) | 46,534 | $30.05 | $1,398,350.00 | (< 1%) 8.05M to 8.0M | |
| 01-Mar-24 9:38 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 01-Mar-24 | Planned Option Sale | 94,480 | $29.04 | $2,743,720.00 | (14%) 657.95K to 563.47K | |
| 05-Mar-24 5:07 PM View: | Atlas Venture Opportunity F... 10% Owner | Dyne Therapeutics, Inc. (DYN) | 01-Mar-24 | Private Sale (Planned) | 29,435 | $30.05 | $884,522.00 | (1%) 2.35M to 2.32M | |
| 01-Mar-24 9:37 PM View: | Scalzo Richard William SVP, Head of Finance & Admin. | Dyne Therapeutics, Inc. (DYN) | 01-Mar-24 | Option Exercise | 9,311 | $1.03 | $9,590.33 | 7% 124.23K to 133.54K | |
| 01-Mar-24 9:37 PM View: | Scalzo Richard William SVP, Head of Finance & Admin. | Dyne Therapeutics, Inc. (DYN) | 01-Mar-24 | Planned Option Sale | 9,311 | $28.25 | $262,999.00 | (7%) 133.54K to 124.23K | |
| 01-Mar-24 9:37 PM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 01-Mar-24 | Option Exercise | 24,260 | $0.73 | $17,709.80 | 17% 143.62K to 167.88K | |
| 05-Mar-24 5:07 PM View: | Atlas Venture Opportunity F... 10% Owner | Dyne Therapeutics, Inc. (DYN) | 01-Mar-24 | Sale (Planned) | 17,099 | $30.05 | $513,825.00 | (< 1%) 2.32M to 2.31M | |
| 01-Mar-24 9:38 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 01-Mar-24 | Option Exercise | 94,480 | $5.54 | $523,419.00 | 17% 563.47K to 657.95K | |
| 01-Mar-24 9:37 PM View: | Scalzo Richard William SVP, Head of Finance & Admin. | Dyne Therapeutics, Inc. (DYN) | 29-Feb-24 | Option Exercise | 3,429 | $1.03 | $3,531.87 | 3% 124.23K to 127.66K | |
| 01-Mar-24 9:37 PM View: | Scalzo Richard William SVP, Head of Finance & Admin. | Dyne Therapeutics, Inc. (DYN) | 29-Feb-24 | Planned Option Sale | 3,429 | $27.50 | $94,297.50 | (3%) 127.66K to 124.23K | |
| 01-Mar-24 9:37 PM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 29-Feb-24 | Option Exercise | 4,268 | $0.73 | $3,115.64 | 3% 143.62K to 147.89K | |
| 01-Mar-24 9:38 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 29-Feb-24 | Option Exercise | 5,520 | $5.54 | $30,580.80 | < 1% 563.47K to 568.99K | |
| 01-Mar-24 9:37 PM View: | McNeill Jonathan Chief Business Officer | Dyne Therapeutics, Inc. (DYN) | 29-Feb-24 | Planned Option Sale | 4,268 | $27.50 | $117,370.00 | (3%) 147.89K to 143.62K | |
| 01-Mar-24 9:38 PM View: | Brumm Joshua T CEO & President Director | Dyne Therapeutics, Inc. (DYN) | 29-Feb-24 | Planned Option Sale | 5,520 | $27.50 | $151,800.00 | (< 1%) 568.99K to 563.47K | |
| 28-Feb-24 7:13 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Dyne Therapeutics, Inc. (DYN) | 28-Feb-24 | Sale (Planned) | 154,674 | $24.84 | $3,841,580.00 | (2%) 8.24M to 8.09M | |
| 28-Feb-24 7:15 PM View: | Rhodes Jason P Director | Dyne Therapeutics, Inc. (DYN) | 28-Feb-24 | Sale (Planned) | 190,920 | $24.84 | $4,741,800.00 | (2%) 8.24M to 8.05M | |
| 28-Feb-24 7:13 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Dyne Therapeutics, Inc. (DYN) | 28-Feb-24 | Sale (Planned) | 36,246 | $24.84 | $900,228.00 | (< 1%) 8.09M to 8.05M | |
| 28-Feb-24 10:00 PM View: | Farwell Wildon Chief Medical Officer | Dyne Therapeutics, Inc. (DYN) | 28-Feb-24 | Private Sale (Planned) | 407 | $25.00 | $10,175.00 | (< 1%) 163.5K to 163.1K | |
| 28-Feb-24 7:13 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Dyne Therapeutics, Inc. (DYN) | 27-Feb-24 | Sale (Planned) | 69,997 | $24.41 | $1,708,340.00 | (< 1%) 8.31M to 8.24M | |
| 28-Feb-24 7:15 PM View: | Rhodes Jason P Director | Dyne Therapeutics, Inc. (DYN) | 27-Feb-24 | Sale (Planned) | 368,699 | $24.41 | $8,998,430.00 | (4%) 8.61M to 8.24M | |
| 28-Feb-24 7:13 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Dyne Therapeutics, Inc. (DYN) | 27-Feb-24 | Sale (Planned) | 298,702 | $24.41 | $7,290,090.00 | (3%) 8.61M to 8.31M | |
| 28-Feb-24 7:15 PM View: | Rhodes Jason P Director | Dyne Therapeutics, Inc. (DYN) | 26-Feb-24 | Private Sale (Planned) | 248,219 | $23.72 | $5,886,670.00 | (3%) 8.86M to 8.61M | |
| 28-Feb-24 7:13 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Dyne Therapeutics, Inc. (DYN) | 26-Feb-24 | Private Sale (Planned) | 201,095 | $23.72 | $4,769,100.00 | (2%) 8.86M to 8.66M | |
| 28-Feb-24 7:13 PM View: | Atlas Venture Fund Xi, L.P. 10% Owner | Dyne Therapeutics, Inc. (DYN) | 26-Feb-24 | Sale (Planned) | 47,124 | $23.72 | $1,117,580.00 | (< 1%) 8.66M to 8.61M |
